| 描述信息 |
As dynamic changes in circulating tumor DNA (ctDNA) variant allele frequency (VAF) reflect real-time therapeutic efficacy, timely treatment modification guided by rising ctDNA VAF, combined with sequential organoid drug screening, may enable precision selection of optimized regimens to counteract evolving resistance in breast cancer. This study presents a novel therapeutic approach by integrating ctDNA dynamics with sequential organoid drug screening to optimize breast cancer treatment. We performed targeted deep sequencing on plasma samples from 71 breast cancer patients, revealing that ctDNA clearance correlates with improved disease-free survival. Additionally, we established 40 breast cancer organoid models, demonstrating the potential of organoid culture supernatants for comprehensive mutation profiling and drug sensitivity testing. Our findings suggest that combining ctDNA monitoring with organoid-based drug screening can dynamically adjust treatment strategies, offering a promising solution to overcome drug resistance and improve therapeutic outcomes. |
